Evidence map›Paper›PMID 35075593›Full record

ArticleHepatology international2022

Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.

Eiichi Ogawa, Makoto Nakamuta, Toshimasa Koyanagi, Aritsune Ooho, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Takeaki Satoh, Kazuhiro Takahashi and 13 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 1 country.

Eiichi OgawaDepartment of General Internal Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. e.ogawa.a65@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-5082-3967
Makoto NakamutaDepartment of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan.
Toshimasa KoyanagiDepartment of Medicine, Fukuoka City Hospital, Fukuoka, Japan.
Aritsune OohoDepartment of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
Norihiro FurusyoGeneral Internal Medicine, Taihaku Avenue Clinic, Fukuoka, Japan.
Eiji KajiwaraKajiwara Clinic, Kitakyushu, Japan.
Kazufumi DohmenDepartment of Internal Medicine, Chihaya Hospital, Fukuoka, Japan.
Akira KawanoDepartment of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Takeaki SatohCenter for Liver Disease, Kokura Medical Center, National Hospital Organization, Kitakyushu, Japan.
Kazuhiro TakahashiDepartment of Medicine, Hamanomachi Hospital, Fukuoka, Japan.
Koichi AzumaDepartment of Medicine, Kyushu Central Hospital, Fukuoka, Japan.
Nobuyuki YamashitaThe Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu, Japan.
Naoki YamashitaDepartment of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan.
Rie SugimotoDepartment of Gastroenterology, Kyushu Cancer Center, Fukuoka, Japan.
Hiromasa AmagaseAmagase Clinic, Kitakyushu, Japan.
Masami KuniyoshiDepartment of Gastroenterology, Kyushu Rosai Hospital, Kitakyushu, Japan.
Yasunori IchikiDepartment of Internal Medicine, JCHO Kyushu Hospital, Kitakyushu, Japan.
Chie MoritaDepartment of Internal Medicine, Kyushu Railway Memorial Hospital, Kitakyushu, Japan.
Masaki KatoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shinji ShimodaDepartment of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hideyuki NomuraDepartment of Internal Medicine, Haradoi Hospital, Fukuoka, Japan.
Jun HayashiKyushu General Internal Medicine Center, Haradoi Hospital, Fukuoka, Japan.
Kyushu University Liver Disease Study (KULDS) Group
National Kyushu Medical Center · JPHaradoi Hospital · JPKyushu Hospital · JPKyushu University · JPFukuoka City Hospital · JPFukuoka Hospital · JPHamanomachi Hospital · JPKitakyushu Municipal Medical Center · JPKyushu Central Hospital of the Mutual Aid Association of Public School Teachers · JPKyushu Rosai Hospital · JPKyushu University Hospital · JPNational Hospital Organization · JPNational Hospital Organization Kyushu Cancer Center · JPNippon Steel Yawata Memorial Hospital · JPSaiseikai Fukuoka General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsOutcome data of sequential hepatitis B virus treatment with tenofovir alafenamide (TAF) are limited. We aimed to assess the effectiveness and renal safety of TAF in chronic hepatitis B (CHB) patients who were previously treated with entecavir (ETV), tenofovir disoproxil fumarate (TDF), or a nucleos(t)ide analogue (NA) combination.

methodsThis multicenter, retrospective, cohort study included 458 consecutive CHB patients who switched to TAF monotherapy after at least 2 years of treatment with another NA. The longitudinal virological/laboratory responses were evaluated up to 96 weeks after switchover. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m

resultsThe proportions of complete viral suppression (CVS) (HBV DNA < 20 IU/mL) at week 96 were 99.0%, 98.5%, and 98.4% in the prior ETV (n = 198), TDF (n = 137), and NA combination (n = 123) groups, respectively. Almost all patients with HBV DNA of 20-2000 IU/mL at baseline achieved CVS at week 96. On multivariable generalized estimated equation analysis, a low quantitative hepatitis surface antigen (qHBsAg) level at baseline was associated with a lower follow-up qHBsAg level (coefficient 0.81, p < 0.001). The eGFR showed greater improvement in patients with CKD compared to those without (coefficient 21.7, p < 0.001). However, the increase of eGFR reached a peak between weeks 24 and 48.

conclusionsBased on this longitudinal data analysis up to 96 weeks, sequential NA therapy with a switch to TAF is a good option to achieve high viral suppression and renal safety.

Indexed as

Hepatitis B, ChronicRenal Insufficiency, ChronicAdenineAlanineAntiviral AgentsCohort StudiesDNA, ViralFemaleHepatitis B Surface AntigensHepatitis B virusHumansMaleRetrospective StudiesTenofovirTreatment OutcomeAdenineAlanineAntiviral AgentsDNA, ViralHepatitis B Surface AntigensTenofovirtenofovir alafenamideEntecavirHepatitis B virusSequential therapyTenofovir alafenamideTenofovir disoproxil fumarate

Identifiers

PMID35075593
OpenAlexW4220722028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.